• News
  • Finance

Analysts raise target for Neurocrine

Wall Street investment bank Leerink Partners on Tuesday raised its price target for San Diego’s Neurocrine Biosciences from $18 to $23 per share after last month’s release of positive data on its proposed treatment for tardive dyskinesia.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!